Pharmaro SRL
2.0 FTEThe score of Pharmaro shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -10 % Total assets -17 % Headcount (avg FTE) 0 %
Accounts of the company itself (not consolidated).
The full file covers 18 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Pharmaro's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 160,527 € | ||||
| Equity | 139,852 € | ||||
| Cash | 195,633 € | ||||
| EBITDA | 212,885 € | ||||
| Total assets | 493,235 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 24 Jun 2026
- Year ended 31 Dec 2024filed on 24 Jun 2025
- Year ended 31 Dec 2023filed on 31 Jul 2024
- Year ended 31 Dec 2022filed on 26 Jul 2023
- Year ended 31 Dec 2021filed on 31 Jul 2022
Pharmaro's financial analysis
- Solvency28.4%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Pharmaro
Pharmaro's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0899.156.742
- VAT number
- BE0899156742
- Peppol
- Registered · 0208:0899156742 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 09 Jul 2008
- Registered office
- 6043 Charleroi
- Size
- Micro · 2.0 FTE
- Latest accounts
- 2025 · filed on 24 Jun 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Pharmaro (SRL) has been based in Charleroi since 2008, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 160,527 € and equity of 139,852 €; its revenue is not published. With 2.0 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 28.4%, below the median of its sector (41.5%).
Companies similar to Pharmaro
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie des Hamendes Retail sale of pharmaceutical products Pont-à-Celles · balance sheet 499,646 €
- Apotheek De Voogt Retail sale of pharmaceutical products Antwerp · balance sheet 492,477 €
- Walemapotheek Retail sale of pharmaceutical products Mechelen · balance sheet 491,415 €
- Medifar Retail sale of pharmaceutical products Izegem · balance sheet 490,803 €
- Secundum Artem Retail sale of pharmaceutical products Etterbeek · balance sheet 496,587 €
- Arendsapotheek Retail sale of pharmaceutical products Harelbeke · balance sheet 488,654 €
- Zwitserse Apotheek Retail sale of pharmaceutical products Wijnegem · balance sheet 498,014 €
- Pharma-Sana Retail sale of pharmaceutical products Schaerbeek · balance sheet 487,904 €
Frequently asked questions about Pharmaro
What is the revenue of Pharmaro?
Pharmaro files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Pharmaro?
In Belgium, the VAT number is the company number prefixed with BE: BE0899156742 for Pharmaro, if the company is VAT-registered. Its company number (CBE) is 0899.156.742.
Where is the registered office of Pharmaro?
According to the CBE register, the registered office of Pharmaro is in 6043 Charleroi.
What is the equity of Pharmaro?
At the close of the 2025 financial year, the equity of Pharmaro amounts to 139,852 €, a solvency of 28.4% of total assets.
How many people work at Pharmaro?
2.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Pharmaro?
The register lists 3 active mandates at Pharmaro. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Pharmaro
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →